Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) EBITDA Margin: 2022-2025

Historic EBITDA Margin for Axsome Therapeutics (AXSM) over the last 3 years, with Sep 2025 value amounting to -26.97%.

  • Axsome Therapeutics' EBITDA Margin rose 3281.00% to -26.97% in Q3 2025 from the same period last year, while for Sep 2025 it was -37.85%, marking a year-over-year increase of 5263.00%. This contributed to the annual value of -72.74% for FY2024, which is 1293.00% up from last year.
  • As of Q3 2025, Axsome Therapeutics' EBITDA Margin stood at -26.97%, which was down 10.20% from -24.47% recorded in Q2 2025.
  • Axsome Therapeutics' EBITDA Margin's 5-year high stood at -6.74% during Q1 2023, with a 5-year trough of -251.76% in Q3 2022.
  • For the 3-year period, Axsome Therapeutics' EBITDA Margin averaged around -71.77%, with its median value being -61.14% (2024).
  • Per our database at Business Quant, Axsome Therapeutics' EBITDA Margin soared by 14,428bps in 2023 and then crashed by 8,296bps in 2024.
  • Over the past 4 years, Axsome Therapeutics' EBITDA Margin (Quarterly) stood at -245.86% in 2022, then skyrocketed by 10,847bps to -137.39% in 2023, then skyrocketed by 7,625bps to -61.14% in 2024, then spiked by 3,281bps to -26.97% in 2025.
  • Its EBITDA Margin stands at -26.97% for Q3 2025, versus -24.47% for Q2 2025 and -46.91% for Q1 2025.